– USA, PA – ArriVent BioPharma, Inc. (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, announced the appointment of Dr. Merdad Parsey (M.D., Ph.D.) to its Board of Directors, bringing decades of executive experience leading global clinical development in the biopharmaceutical industry.
Dr. Parsey added, “ArriVent is poised to broadly change the cancer treatment landscape with differentiated candidates like firmonertinib that address key unmet needs and their pipeline of next-generation ADC programs that use diverse approaches. I am excited to partner with management and the Board of Directors to help shape the clinical development and commercial strategy for their growing portfolio.”
About Dr. Merdad Parsey
Dr. Merdad Parsey most recently was serving as CMO and EVP of Gilead Sciences, Inc. Before Gilead, he held positions of increasing responsibility at Genentech, Inc., a member of the Roche Group, most recently as SVP in Genentech Research and Early Development, overseeing clinical development, quality, compliance, informatics and clinical operations functions. He also served as President and CEO of 3-V Biosciences, Inc., now Sagimet Biosciences, Inc., and has served on the Board of Directors since 2010. Earlier in his career, he held development roles at Sepracor, Inc., Regeneron Pharmaceuticals, Inc., and Merck, Inc,. and served as Assistant Professor of Medicine and Director of Critical Care Medicine at New York University School of Medicine.
Dr. Merdad Parsey completed his M.D. and Ph.D. in immunology at the University of Maryland, Baltimore, his residency in Internal Medicine at Stanford University, and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.
About ArriVent
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.
For more: https://arrivent.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.